Blood diamond: Milestone for Closed Loop Medicine in hypertension trial

Closed Loop Medicine has recruited its first patient into a novel PhIV precision medicine interventional clinical trial for patients with high blood pressure.

The UK clinical stage therapeutics company is developing drug + digital combination products.

The new clinical trial – tagged Personal COVID BP – will see up to 1,000 patients recruited for a study investigating whether a combination product that links a drug to a smart phone app can enable patients to personalise and optimise their therapy regimen to treat hypertension.

Crucially the technology in the study allows patients shielding from COVID-19 to control their blood pressure remotely in a home setting environment.

The interventional arm of the study, in which up to 200 patients are involved, will see patients receive drug therapy while using an app to monitor blood pressure, as well as any potential side effects. This will help to determine whether the approach can be used to identify the optimum balance of tolerable side effects and controlled blood pressure.